Biogen   3Q Revenues: $2.8 billion (+11%) 3Q Earnings: $1.0 billion (+19%) YTD Revenues: $7.9 billion (+12%) YTD Earnings: $2.8 billion (+34%) Comments: Total multiple sclerosis product sales were $2.2 billion, up 5% in the quarter. TECFIDERA revenues were $937 million in the quarter, up 6%. Interferon revenues, including AVONEX and PLEGRIDY, were $785 million, up 14%. TYSABRI revenues were down 4% to $480 million. Revenues relating to RITUXAN and GAZYVA from Biogen’s unconsolidate...